View Financial HealthBlack Bird Biotech 配当と自社株買い配当金 基準チェック /06Black Bird Biotech配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 18Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/16/2024, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 17+ 1 more updateBlack Bird Biotech, Inc. Appoints Nelson Grist as New CEOBlack Bird Biotech, Inc. announced that it has appointed public markets veteran Nelson Grist as its Chief Executive Officer (CEO). With over 15 years of experience in executive positions at publicly traded companies focused on emerging technologies in a variety of industries, Grist seeks to expand the Company’s strategic growth plan beyond its current agricultural offerings into burgeoning verticals such as innovative wellness and healthcare solutions through both organic growth and M&A activities. Mr. Grist has over 15 years’ experience serving in a Chief Executive Officer role at multiple publicly-traded companies focused on the health and wellness sector. Beyond his leadership roles in capital markets, Mr. Grist has extensive experience as a global CPG (customer packaged goods) and direct selling industry executive with progressive international leadership and general management experience across North America, Latin America, and Europe. He is a proven transformational leader, strategic thinker, and change agent, with a track record of creating shareholder value through profitable growth, brand development, performance improvement and team building. Mr. Grist’s experience also extends into the areas of P&L management, organizational design, consumer marketing, commercial capability enhancement, supply chain, talent development, and bringing cross-functional work groups together with a common goal to produce outstanding results.お知らせ • Apr 02Black Bird Biotech, Inc. announced delayed annual 10-K filingOn 04/01/2024, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 11/15/2023, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/15/2023, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 08/16/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/16/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 13William J. Lobell Appoints as Executive Vice President of Sales and Development for Black Bird Biotech, IncOn April 7, 2022, William J. LoBell was appointed as Executive Vice President of Sales and Development for Black Bird Biotech, Inc. From December 2021 until April 2022, Mr. LoBell served as a consultant to Barry's Restore It All Products.お知らせ • Apr 01Black Bird Biotech, Inc. announced delayed annual 10-K filingOn 03/31/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 08/16/2021, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Digital Development Partners, Inc. announced delayed 10-Q filingOn 05/17/2021, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Digital Development Partners, Inc. announced delayed annual 10-K filingOn 03/31/2021, Digital Development Partners, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 10Digital Development Partners, Inc. Obtains Exclusive Worldwide Distribution Rights and 80% Reduction in Royalty Rate to Disruptive EPA Registered Plant-Based Biopesticide MiteXstreamDigital Development Partners, Inc. announced that it has obtained the exclusive worldwide distribution rights and an 80% reduction in the royalty rate to the disruptive plant-based biopesticide MiteXstream, an effective eradicator of spider mites, a pest that destroys crops, especially cannabis, hops, coffee, and house plants, as well as molds and mildew. Spider Mites are an industry wide issue. In fact, in addition to cannabis, spider mites are a significant pest in the production of hemp and hops, among other agricultural products. MiteXstream eliminates spider mites and their eggs, with no risk of plant damage. Based upon independent lab testing, users of MiteXstream are able to treat their cannabis plants through the day of harvest and still satisfy state-level pesticide testing standards, creating a tremendous competitive advantage, the MiteXstream secret sauce.お知らせ • Nov 17Digital Development Partners, Inc. announced delayed 10-Q filingOn 11/16/2020, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 19Digital Development Partners, Inc. announced delayed 10-Q filingOn 08/18/2020, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.決済の安定と成長配当データの取得安定した配当: BBBTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: BBBTの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Black Bird Biotech 配当利回り対市場BBBT 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (BBBT)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (BBBT) (最長3年)n/a注目すべき配当: BBBTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: BBBTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: BBBTの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: BBBTが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 18:38終値2026/05/21 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Black Bird Biotech, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 18Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/16/2024, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 17+ 1 more updateBlack Bird Biotech, Inc. Appoints Nelson Grist as New CEOBlack Bird Biotech, Inc. announced that it has appointed public markets veteran Nelson Grist as its Chief Executive Officer (CEO). With over 15 years of experience in executive positions at publicly traded companies focused on emerging technologies in a variety of industries, Grist seeks to expand the Company’s strategic growth plan beyond its current agricultural offerings into burgeoning verticals such as innovative wellness and healthcare solutions through both organic growth and M&A activities. Mr. Grist has over 15 years’ experience serving in a Chief Executive Officer role at multiple publicly-traded companies focused on the health and wellness sector. Beyond his leadership roles in capital markets, Mr. Grist has extensive experience as a global CPG (customer packaged goods) and direct selling industry executive with progressive international leadership and general management experience across North America, Latin America, and Europe. He is a proven transformational leader, strategic thinker, and change agent, with a track record of creating shareholder value through profitable growth, brand development, performance improvement and team building. Mr. Grist’s experience also extends into the areas of P&L management, organizational design, consumer marketing, commercial capability enhancement, supply chain, talent development, and bringing cross-functional work groups together with a common goal to produce outstanding results.
お知らせ • Apr 02Black Bird Biotech, Inc. announced delayed annual 10-K filingOn 04/01/2024, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 11/15/2023, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/15/2023, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 08/16/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/16/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 13William J. Lobell Appoints as Executive Vice President of Sales and Development for Black Bird Biotech, IncOn April 7, 2022, William J. LoBell was appointed as Executive Vice President of Sales and Development for Black Bird Biotech, Inc. From December 2021 until April 2022, Mr. LoBell served as a consultant to Barry's Restore It All Products.
お知らせ • Apr 01Black Bird Biotech, Inc. announced delayed annual 10-K filingOn 03/31/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 08/16/2021, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Digital Development Partners, Inc. announced delayed 10-Q filingOn 05/17/2021, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Digital Development Partners, Inc. announced delayed annual 10-K filingOn 03/31/2021, Digital Development Partners, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 10Digital Development Partners, Inc. Obtains Exclusive Worldwide Distribution Rights and 80% Reduction in Royalty Rate to Disruptive EPA Registered Plant-Based Biopesticide MiteXstreamDigital Development Partners, Inc. announced that it has obtained the exclusive worldwide distribution rights and an 80% reduction in the royalty rate to the disruptive plant-based biopesticide MiteXstream, an effective eradicator of spider mites, a pest that destroys crops, especially cannabis, hops, coffee, and house plants, as well as molds and mildew. Spider Mites are an industry wide issue. In fact, in addition to cannabis, spider mites are a significant pest in the production of hemp and hops, among other agricultural products. MiteXstream eliminates spider mites and their eggs, with no risk of plant damage. Based upon independent lab testing, users of MiteXstream are able to treat their cannabis plants through the day of harvest and still satisfy state-level pesticide testing standards, creating a tremendous competitive advantage, the MiteXstream secret sauce.
お知らせ • Nov 17Digital Development Partners, Inc. announced delayed 10-Q filingOn 11/16/2020, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 19Digital Development Partners, Inc. announced delayed 10-Q filingOn 08/18/2020, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.